Precigen (PGEN) Stock Price, News & Analysis

Company Overview

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Key Stats

• Today's Range: $1.53 to $1.57
• 50-Day Range: $1.17 to $1.97
• 52-Week Range: $0.65 to $2.17
• Volume: 140,499 shs
• Average Volume: 1.78 million shs
• Market Capitalization: $460.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Precigen Stock Analysis - MarketRank™

Precigen scored higher than 74% of companies evaluated by MarketBeat, and ranked 268th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Precigen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Precigen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Precigen are expected to grow in the coming year, from ($0.32) to ($0.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Precigen is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precigen is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precigen has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.62% of the float of Precigen has been sold short.

Short Interest Ratio / Days to Cover

Precigen has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Precigen has recently increased by 6.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precigen does not currently pay a dividend.

Dividend Growth

Precigen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.77

Percentage of Shares Shorted

15.62% of the float of Precigen has been sold short.

Short Interest Ratio / Days to Cover

Precigen has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Precigen has recently increased by 6.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Precigen has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Precigen this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Precigen insiders have not sold or bought any company stock.

Percentage Held by Insiders

44.90% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 33.51% of the stock of Precigen is held by institutions.

PGEN Stock Analysis - Frequently Asked Questions

How have PGEN shares performed this year?

Precigen's stock was trading at $1.12 at the beginning of the year. Since then, PGEN shares have increased by 37.5% and is now trading at $1.54.
View the best growth stocks for 2025 here.

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) posted its quarterly earnings results on Wednesday, March, 19th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. The biotechnology company had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.30 million. Precigen had a negative trailing twelve-month return on equity of 123.06% and a negative net margin of 3,521.68%.
Read the conference call transcript.

Who are Precigen's major shareholders?

Precigen's top institutional shareholders include Cambridge Investment Research Advisors Inc. (0.07%), Exchange Traded Concepts LLC (0.02%) and Apella Capital LLC (0.01%). Insiders that own company stock include Helen Sabzevari, Randal J Kirk, Steven Frank, Jeffrey Thomas Perez, Donald P Lehr, Dean J Mitchell, Jeffrey B Kindler, Harry Jr Thomasian and Rutul R Shah.
View institutional ownership trends.

How do I buy shares of Precigen?

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include Nordic American Tankers (NAT), ZIOPHARM Oncology (ZIOP), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Hess (HES) and Boeing (BA).

Company Calendar

• Last Earnings: 3/19/2025
• Today: 4/29/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PGEN
• CIK: 1356090
• Web: www.precigen.com
• Phone: (301) 556-9900
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +351.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-95,900,000.00
• Net Margins: -3,521.68%
• Pretax Margin: -3,573.10%
• Return on Equity: -123.06%
• Return on Assets: -87.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.63
• Quick Ratio: 1.63

Sales & Book Value

• Annual Sales: $3.93 million
• Price / Sales: 116.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 3.23

Miscellaneous

• Outstanding Shares: 294,043,000
• Free Float: 161,371,000
• Market Cap: $455.77 million
• Optionable: Optionable
• Beta: 1.70